# A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

> **NCT06755515** · PHASE2,PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Shandong New Time Pharmaceutical Co., LTD** · enrollment: 510 (estimated)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** Rulonilimab
- **DRUG:** Placebo
- **DRUG:** cisplatin/carboplatin + paclitaxel ± bevacizumab

## Key facts

- **NCT ID:** NCT06755515
- **Lead sponsor:** Shandong New Time Pharmaceutical Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-09-26
- **Primary completion:** 2028-09
- **Final completion:** 2028-09
- **Target enrollment:** 510 (ESTIMATED)
- **Last updated:** 2025-01-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06755515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06755515, "A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT06755515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*